{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/","result":{"pageContext":{"chapter":{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD","depth":2,"htmlHeader":"<!-- begin field 30d87d72-565d-4ee9-8e02-3fc1e894679f --><h2>Diagnosis of chronic obstructive pulmonary disease</h2><!-- end field 30d87d72-565d-4ee9-8e02-3fc1e894679f -->","summary":"","htmlStringContent":"<!-- begin item 8b0b0f05-e60f-47d9-b767-25d907376b65 --><!-- begin field 2bba878a-4c7a-4511-9b5b-a76e00d88584 --><p><strong>Diagnosis of COPD is based on typical clinical features supported by spirometry.</strong></p><ul><li><strong>Suspect COPD in people aged over 35 years with a <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/background-information/risk-factors/\">risk factor</a> (such as smoking, occupational or environmental exposure) and one or more of the following symptoms:</strong><ul><li>Breathlessness — typically persistent, progressive over time, and worse on exertion.</li><li>Chronic/recurrent cough.</li><li>Regular sputum production.</li><li>Frequent lower respiratory tract infections.</li><li>Wheeze.</li></ul></li><li><strong>Other symptoms which may be present include:</strong><ul><li>Weight loss, anorexia and fatigue — common in severe COPD but <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#differential-diagnosis\">other causes</a> must be considered.</li><li>Waking at night with breathlessness.</li><li>Ankle swelling – consider cor pulmonale.</li><li>Chest pain – uncommon in COPD, consider <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#differential-diagnosis\">other causes</a>.</li><li>Haemoptysis – uncommon in COPD, consider <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#differential-diagnosis\">other causes</a>.</li><li>Reduced exercise tolerance.</li></ul></li><li><strong>Examination may be normal. Where present, signs may include:</strong><ul><li>Cyanosis.</li><li>Raised jugular venous pressure and/or peripheral oedema (may indicate cor pulmonale).</li><li>Cachexia.</li><li>Hyperinflation of the chest.</li><li>Use of accessory muscles and/or pursed lip breathing.</li><li>Wheeze and/or crackles on auscultation of the chest.</li></ul></li><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#spirometry\">Spirometry</a> is required for confirmation of diagnosis:</strong><ul><li>A post bronchodilator FEV1/FVC less than 0.7 confirms persistent airflow obstruction.</li><li>Consider other causes in older people without typical symptoms of COPD who have an FEV1/FVC ratio less than 0.7.</li><li>Consider COPD in younger people who have symptoms of COPD, even when their FEV1/FVC ratio is above 0.7.</li></ul></li><li><strong>Consider <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#differential-diagnosis\">alternative diagnoses</a> and be aware that COPD can co-exist with other conditions.</strong><ul><li>Differentiating asthma from COPD in adults can be difficult.<ul><li>For more information on diagnosis of asthma, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/asthma/\">Asthma</a>.</li></ul></li></ul></li><li><strong>Consider alpha-1-antitrypsin deficiency</strong> if the person is younger than 40 years of age or has a family history.</li></ul><!-- end field 2bba878a-4c7a-4511-9b5b-a76e00d88584 --><!-- end item 8b0b0f05-e60f-47d9-b767-25d907376b65 -->","topic":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f","topicId":"e48489e8-63d1-4a04-bc5b-07e36a76af58","topicName":"Chronic obstructive pulmonary disease","slug":"chronic-obstructive-pulmonary-disease","lastRevised":"Last revised in October 2020","chapters":[{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ccd2981-1bc9-5357-86d2-cbf578b57adb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes"},{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update"}]},{"id":"d28cbe2c-ffc9-58ab-913c-3afa52c28841","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"99f07881-2c1a-5874-8cd2-3f10dcb385fa","slug":"goals","fullItemName":"Goals"},{"id":"85c2e06f-fe1e-532b-8752-0337ca19cfe3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f6fa4f07-a45d-5c3e-8c59-2054ea5ecd38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"defe1786-7b6d-5c90-a7f4-0871262dd84f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6356570-e32f-5480-89d6-026b80bb055d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0433c46f-8e2f-53b3-a392-aca635b35160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29a2fdef-c0c3-5bb6-9c12-21d649ed27bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"715af617-76e1-5846-9262-1616f0003270","slug":"definition","fullItemName":"Definition"},{"id":"6f383baf-ff39-58db-b933-24b4c5feb5f8","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"7fe9ff8f-68ba-5f97-91ab-8d23c907b1cf","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4bcdbaec-2487-5733-812a-7ec514939f8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c7c94e20-91a7-5b3d-b8dd-0d4f8d5c023c","slug":"complications","fullItemName":"Complications"}]},{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD"},{"id":"93fac9cc-fc19-5440-8330-f6f56941ddb6","slug":"diagnosis-acute-exacerbation","fullItemName":"Diagnosis - acute exacerbation"}]},{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"4aafe1b6-b17a-51d8-a8f0-104880ac3722","slug":"stable-copd","fullItemName":"Scenario: Stable COPD"},{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation"},{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD"},{"id":"f1d4be42-b98a-55de-860a-3be931c97c1c","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists"},{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"f45aa048-e0b1-55dc-9f40-68f5af6d3b61","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics"},{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline"},{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics"}]},{"id":"81fd9c2f-91c3-5726-b50a-85fc169646d3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b91263e-7dc1-51aa-9976-bd92619d846e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ac29e092-9d36-550e-99e2-c6b478d21c00","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"737d1a20-607a-560b-8522-2ddb2237249b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bec938e3-108f-5f91-9c9b-2c289bae4e07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dc4c2f7c-85ce-5ba5-a2ef-149ee8a9d54d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51ecdba0-ee93-5792-af12-b38cb8f06b8c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9ad1cd46-bf5b-505f-a6d9-bad7287adccc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"6332fe99-ef45-5aa9-b2bc-293b17f346f5","slug":"cor-pulmonale","fullItemName":"Cor pulmonale","depth":3,"htmlHeader":"<!-- begin field ff333c60-b456-4f43-8b28-a76e00d632ba --><h3>Cor pulmonale</h3><!-- end field ff333c60-b456-4f43-8b28-a76e00d632ba -->","summary":null,"htmlStringContent":"<!-- begin item 37ff6848-2b83-4be8-88e7-a76e00d630c2 --><!-- begin field 0b97a665-1495-428a-bf99-a76e00d632ba --><ul><li>Cor pulmonale is right heart failure secondary to lung disease, and is caused by pulmonary hypertension as a consequence of hypoxia.</li><li>Suspect cor pulmonale in people with:<ul><li>Peripheral oedema.</li><li>Raised jugular venous pressure.</li><li>Systolic parasternal heave.</li><li>A loud pulmonary second heart sound (over the second left intercostal space).</li><li>Hepatomegaly.</li></ul></li><li>Other causes of peripheral oedema should be considered.</li></ul><!-- end field 0b97a665-1495-428a-bf99-a76e00d632ba --><!-- end item 37ff6848-2b83-4be8-88e7-a76e00d630c2 -->","subChapters":[]},{"id":"8298be9e-20e3-55ba-bd9e-da5ac8eac811","slug":"assessment","fullItemName":"Assessment","depth":3,"htmlHeader":"<!-- begin field b2592c58-1166-4a3b-bb4c-a76e00d646ad --><h3>How should I assess a person with suspected COPD?</h3><!-- end field b2592c58-1166-4a3b-bb4c-a76e00d646ad -->","summary":null,"htmlStringContent":"<!-- begin item d06e8174-a680-4b97-a288-a76e00d64490 --><!-- begin field 6deb13d8-e3d2-460c-85d9-a76e00d646ad --><p><strong>Take a history asking about:</strong></p><ul><li>Onset, variability and progression of <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/\">symptoms</a> such as:<ul><li>Breathlessness — assess severity using the <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#medical-research-council-dyspnoea-scale\">Medical Research Council (MRC) dyspnoea scale</a>.</li><li>Cough and sputum production — ask about haemoptysis and consider <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#differential-diagnosis\">other causes</a>.</li><li>Peripheral oedema — consider <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#cor-pulmonale\">cor pulmonale</a>.</li><li>Weight loss – consider <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#differential-diagnosis\">other causes</a>.</li></ul></li><li>Exposure to risk factors including:<ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/background-information/risk-factors/\">Smoking</a> — if the person is a current smoker document pack-years smoked (number of cigarette smoked per day divided by 20 multiplied by number of years smoked).</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/background-information/risk-factors/\">Occupational or environmental exposures</a>.</li></ul></li><li>Impact of symptoms on daily life and occupation:<ul><li>Impact of COPD on wellbeing and daily life can be assessed using the COPD Assessment test (CAT) — available in the <a href=\"https://goldcopd.org/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"c3ecf999-7696-431f-a2a0-ab1200f3861a\">GOLD guidelines</a>.</li></ul></li><li>Previous exacerbations or hospitalization.</li><li>Past medical history and comorbidities including:<ul><li>Anxiety and depression.</li><li>Cardiovascular disease and metabolic syndrome.</li><li>Lung or liver disease.</li><li>Osteoporosis.</li><li>Asthma.</li></ul></li><li>Family history including:<ul><li>Lung or liver disease – consider <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/background-information/risk-factors/\">underlying causes</a> such as alpha-1-antitrypsin deficiency.</li></ul></li></ul><p><strong>Examine the person:</strong></p><ul><li>Carry out a general examination including vital signs (such as heart rate, blood pressure, temperature, and pulse oximetry).</li><li>Examine the chest and check for peripheral oedema and other signs of <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#cor-pulmonale\">cor pulmonale</a>.</li><li>Measure weight and height to calculate body mass index (weight in kg/height in m<sup>2</sup>).</li></ul><h4>Arrange investigations including:</h4><ul><li><strong>Chest X-ray </strong>— to help exclude <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#differential-diagnosis\">other causes</a> (such as lung cancer, bronchiectasis, tuberculosis, and heart failure).</li><li><strong>Full blood count </strong>—<strong> </strong>to identify anaemia or polycythaemia.</li><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#spirometry\">Spirometry</a>.</strong><ul><li>Measure post-bronchodilator spirometry to confirm the diagnosis of COPD — do not routinely perform reversibility testing as part of diagnostic work up.</li></ul></li></ul><p><strong>Depending on the clinical situation, additional investigations may be indicated such as:</strong></p><ul><li>Sputum culture – if sputum is purulent and persistent (to identify organisms).</li><li>Serial home peak flow measurements – to exclude asthma if diagnosis is in doubt.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/asthma/\">Asthma</a>.</li></ul></li><li>ECG and serum natriuretic peptides – if cardiac disease or pulmonary hypertension are suspected.<ul><li>Echocardiogram may also be indicated.</li></ul></li><li>CT thorax – if symptoms seem disproportionate to spirometry measurements; <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#differential-diagnosis\">another diagnosis</a> (such as fibrosis or bronchiectasis) is suspected, or an abnormality on chest x-ray requires further investigation.<ul><li>Seek specialist advice where appropriate.</li></ul></li><li>Serum alpha-1-antitrypsin.<ul><li>Consider alpha-1-antitrypsin deficiency in people with early onset of symptoms, minimal smoking history or a positive family history.</li><li>Referral to a specialist for management and screening of family members is required if alpha-1-antitrypsin deficiency is identified.</li></ul></li></ul><!-- end field 6deb13d8-e3d2-460c-85d9-a76e00d646ad --><!-- end item d06e8174-a680-4b97-a288-a76e00d64490 -->","subChapters":[]},{"id":"94fec613-e6f5-5ebb-92a2-0823d811d730","slug":"spirometry","fullItemName":"Spirometry","depth":3,"htmlHeader":"<!-- begin field c081abde-9167-4430-a08d-a76e00d9ca6c --><h3>Spirometry</h3><!-- end field c081abde-9167-4430-a08d-a76e00d9ca6c -->","summary":null,"htmlStringContent":"<!-- begin item acca4680-3a5b-4793-a2f4-a76e00d9c855 --><!-- begin field 93748555-9ecb-4748-a3b7-a76e00d9ca6c --><ul><li>Post-bronchodilator spirometry should be performed and interpreted by an appropriately trained health professional to confirm the diagnosis of chronic obstructive pulmonary disease (COPD).<ul><li>Spirometry should be carried out 15–20 minutes after the person has inhaled a short-acting bronchodilator (for example 400 micrograms salbutamol delivered via a spacer device — local protocols may vary).</li><li>Airflow obstruction is defined as a post bronchodilator ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) of less than 0.7.<ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#differential-diagnosis\">Other causes</a> should be considered in older people who have a FEV1/FVC ratio below 0.7 but do <em>not have </em>typical symptoms of COPD.</li><li>COPD should be considered in younger people with typical symptoms even if FEV1/FVC ratio is above 0.7.</li></ul></li></ul></li><li>Where post-bronchodilator FEV1/FVC ratio is less than 0.7, severity of airflow obstruction is graded according to reduction in FEV1 compared to appropriate reference values (based on age, sex, height and ethnicity):<ul><li>Stage 1, mild — FEV1 80% of predicted value or higher.</li><li>Stage 2, moderate — FEV1 50–79% of predicted value.</li><li>Stage 3, severe — FEV1 30–49% of predicted value.</li><li>Stage 4, very severe — FEV1 less than 30% of predicted value <em>or</em> FEV1 less than 50% with respiratory failure.</li></ul></li><li>Routine spirometry reversibility testing is <em>not</em> recommended.</li><li>Spirometry should be performed at diagnosis, when diagnosis is reconsidered and for monitoring of disease severity and progression.</li></ul><!-- end field 93748555-9ecb-4748-a3b7-a76e00d9ca6c --><!-- end item acca4680-3a5b-4793-a2f4-a76e00d9c855 -->","subChapters":[]},{"id":"f49c83d0-ee24-5081-9070-d53171da28f3","slug":"medical-research-council-dyspnoea-scale","fullItemName":"Medical Research Council dyspnoea scale","depth":3,"htmlHeader":"<!-- begin field 88dc80c6-a294-4c0c-a2ba-a76e00da309a --><h3>Medical Research Council (MRC) dyspnoea scale</h3><!-- end field 88dc80c6-a294-4c0c-a2ba-a76e00da309a -->","summary":null,"htmlStringContent":"<!-- begin item fbf3eaa0-7331-4baa-8ce9-a76e00da2e7c --><!-- begin field d7f6b38c-7961-44aa-9ba7-a76e00da309a --><p><strong>Table 1.</strong> Medical Research Council (MRC) dyspnoea scale.</p><table data-table-id=\"be28058c-b927-4378-bfb5-acce014f7a80\"><thead><tr><th scope=\"col\">Grade</th><th scope=\"col\">Level of activity</th></tr></thead><tbody><tr><td>1</td><td>Not troubled by breathlessness except during strenuous exercise</td></tr><tr><td>2</td><td>Short of breath when hurrying or walking up a slight hill</td></tr><tr><td>3</td><td>Walks slower than contemporaries on the level because of breathlessness, or has to stop for breath when walking at own pace</td></tr><tr><td>4</td><td>Stops for breath after walking about 100 m or after a few minutes on the level</td></tr><tr><td>5</td><td>Too breathless to leave the house, or breathless when dressing or undressing</td></tr><tr><td colspan=\"2\"><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>]</td></tr></tbody></table><!-- end field d7f6b38c-7961-44aa-9ba7-a76e00da309a --><!-- end item fbf3eaa0-7331-4baa-8ce9-a76e00da2e7c -->","subChapters":[]},{"id":"f3b71a3c-da69-5cec-aacb-c8174312d8d4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis","depth":3,"htmlHeader":"<!-- begin field 97c3e5f1-5b05-44b0-a1e3-a76e00d6630b --><h3>What else might it be?</h3><!-- end field 97c3e5f1-5b05-44b0-a1e3-a76e00d6630b -->","summary":null,"htmlStringContent":"<!-- begin item 07da72a1-ef8c-4a3c-94f1-a76e00d6606a --><!-- begin field 0e1c743c-c554-48d2-87ab-a76e00d6630b --><ul><li><strong>The differential diagnosis of chronic obstructive pulmonary disease (COPD) includes:</strong><ul><li><strong>Asthma</strong> — COPD and asthma can be difficult to distinguish clinically and may co-exist.<ul><li>Consider asthma if the person has a family history, other atopic disease, or nocturnal or variable symptoms, is a non-smoker, or experienced onset of symptoms at younger than 35 years of age.</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/asthma/\">Asthma</a>.</li></ul></li><li><strong>Bronchiectasis</strong> — clinical features include copious sputum, frequent chest infections, a history of childhood pneumonia, and coarse lung crepitations.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/bronchiectasis/\">Bronchiectasis</a>.</li></ul></li><li><strong>Heart failure</strong> — clinical features include breathlessness when lying flat, a history of ischaemic heart disease, and fine lung crepitations.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>.</li></ul></li><li><strong>Lung cancer</strong> — consider if the person has a persistent cough, haemoptysis, weight loss, or persistent hoarse voice.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/lung-pleural-cancers-recognition-referral/\">Lung and pleural cancers - recognition and referral</a>.</li></ul></li><li><strong>Interstitial lung disease</strong> (such as asbestosis, pneumoconiosis, fibrosing alveolitis, or sarcoidosis) — clinical features include a dry cough and fine lung crepitations.</li><li><strong>Anaemia</strong> — clinical features include fatigue, breathlessness, and palpitations.<ul><li>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/anaemia-iron-deficiency/\">Anaemia - iron deficiency</a> and <a class=\"topic-reference external-reference\" href=\"/topics/anaemia-b12-folate-deficiency/\">Anaemia - B12 and folate deficiency</a>.</li></ul></li><li><strong>Tuberculosis (TB)</strong> — clinical features include persistent productive cough, which may be associated with breathlessness and haemoptysis. May co-exist with COPD.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/tuberculosis/\">Tuberculosis</a>.</li></ul></li><li><strong>Cystic fibrosis.</strong></li><li><strong>Upper airway obstruction</strong> (for example tracheal tumour).</li></ul></li><li>For detailed information on the differential diagnosis of cough and breathlessness, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cough/\">Cough</a> and <a class=\"topic-reference external-reference\" href=\"/topics/breathlessness/\">Breathlessness</a>.</li></ul><!-- end field 0e1c743c-c554-48d2-87ab-a76e00d6630b --><!-- end item 07da72a1-ef8c-4a3c-94f1-a76e00d6606a -->","subChapters":[]},{"id":"2dec092c-ab80-5380-8b46-16651a51455e","slug":"basis-for-recommendation-99b","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 703f7bf7-922e-4455-8022-a76e00dbf279 --><h3>Basis for recommendation</h3><!-- end field 703f7bf7-922e-4455-8022-a76e00dbf279 -->","summary":null,"htmlStringContent":"<!-- begin item 99bb0040-282b-4a66-b432-a76e00dbf05c --><!-- begin field f840d9b5-3113-4208-9b5c-a76e00dbf279 --><h4>Clinical features</h4><p>The information on the clinical features of COPD is based on the clinical guidelines <em>Diagnosis and initial treatment of asthma, COPD and asthma-COPD overlap</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GINA and GOLD, 2017</a>], <em>COPD-X: concise guide for primary care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>], <em>Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 report</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>] and <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Gentry, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BMJ Best Practice, 2018</a>].</p><ul><li>Chronic progressive breathlessness is characteristic of COPD — up to 30% of people with COPD have cough productive of sputum [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>].</li><li>It can be very difficult to differentiate COPD from asthma (especially in older adults and smokers) — in some people clinical features of both conditions may be present [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GINA and GOLD, 2017</a>].</li></ul><h4>Assessment</h4><p>The recommendations on assessment of a person with suspected COPD are based on the clinical guidelines <em>Diagnosis and initial treatment of asthma, COPD and asthma-COPD overlap</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GINA and GOLD, 2017</a>], <em>COPD-X: concise guide for primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>], <em>Chronic obstructive pulmonary disease (COPD): best practice guide</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Scottish Government, 2017</a>], <em>Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 report</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>], <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Miller, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Postma, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Gentry, 2017</a>].</p><ul><li><strong>Stepwise approach to diagnosis</strong><ul><li>Clinical guidance from GOLD and NICE agrees on a stepwise approach to the diagnosis of COPD through thorough history and examination followed by confirmation on spirometry. </li><li>Symptoms of COPD may precede airflow limitation on spirometry or conversely, significant airflow limitation may be identified in the absence of symptoms such as chronic breathlessness and/or cough and sputum production [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>].</li></ul></li><li><strong>Comorbidities</strong><ul><li>COPD is often part of multimorbidity (especially in older people). Identification and appropriate treatment of comorbid conditions (such as cardiovascular disease, metabolic syndrome, osteoporosis, anxiety, depression and lung cancer) can reduce risk of mortality and hospitalization and improve quality of life [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Rabe, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>].</li><li>A meta-analysis (11 studies, n=47,695,183 with COPD and 47,924,876 without COPD) found that the prevalence of cardiovascular comorbidities [OR 1.90, 95% CI 1.59-2.28], cerebrovascular comorbidities (OR 1.84, 95% CI 1.47-2.31), hypertension (OR 1.45, 95% CI 1.31-1.61), diabetes mellitus (OR 1.22, 95% CI 1.07-1.38), neurological and psychiatric disorders (OR 1.78, 95% CI 1.48-2.14), gut and renal disorders (OR 1.96, 95% CI 1.43-2.68), musculoskeletal disorders (OR 1.51, 95% CI 1.27-1.78), and cancer (OR 1.67, 95% CI 1.25-2.23; P = .0005) were significantly higher in COPD patients than in non-COPD controls [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Yin, 2017</a>].</li></ul></li><li><strong>Assessment of severity is important in guiding treatment decisions and prognosis</strong><ul><li>NICE guidance states that as COPD is a heterogeneous condition, no single measure can adequately assess disease severity. Instead many factors associated with prognosis such as FEV1; smoking status; breathlessness on the <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/diagnosis/diagnosis-copd/#medical-research-council-dyspnoea-scale\">MRC scale</a>; presence of chronic hypoxia and/or cor pulmonale; low BMI; severity and frequency of exacerbations; hospital admissions; symptom burden (for example, on the COPD Assessment Test [CAT] score); exercise capacity; criteria for long-term oxygen therapy/home noninvasive ventilation; multimorbidity; and frailty should be taken into account. Use of multidimensional indices (such as BODE) should not be used to assess prognosis as they are unreliable and time-consuming [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>].</li></ul></li><li><strong>Examination</strong><ul><li>Clinical signs of COPD may not develop until lung function becomes severely impaired – absence of physical signs does not exclude a diagnosis of COPD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>].</li><li>Pulse oximetry should not be used as a diagnostic tool but can be helpful in determining severity of COPD and help direct treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">All Wales Medicine Strategy Group, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>].</li><li>Body mass index (BMI) — weight loss is common in severe and very severe COPD and negatively affects COPD prognosis. It may also be a sign of serious co-existing disease such as TB or lung cancer and always requires investigation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>].</li></ul></li><li><strong>Investigations</strong><ul><li><strong>Spirometry </strong>— clinical guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>] agrees that post-bronchodilator spirometry is a reproducible and objective measurement of airflow limitation and should be used for confirmation of COPD diagnosis following thorough clinical assessment.<ul><li>Spirometry should not be used in isolation to clinically diagnose COPD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>] — 20-30% of patients who have a clinical diagnosis of COPD do not have airflow limitation on spirometry [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>].</li><li>In people with borderline spirometry, other causes should be considered and investigated appropriately (referral may be indicated) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Postma, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>].</li><li>Limitations associated with the use of a fixed FEV1/FVC ratio for all ages include the possibility of over-diagnosis in the elderly (FEV1:FVC ratio reduces with age due to age-related physiological changes) and under-diagnosis in adults aged under 45 years (especially in mild disease) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Postma, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Rennard, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>].</li><li>NICE guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>] recommends that routine reversibility testing (which should not be confused with or equated to post-bronchodilator spirometry measurement) is not needed for most people as:<ul><li>Repeated FEV1 measurements can show small spontaneous fluctuations.</li><li>Results of reversibility test performed on different occasions can be inconsistent and not reproducible.</li><li>Over-reliance on single reversibility test may be misleading unless change in FEV1 is greater than 400ml.</li><li>The definition of significant change is arbitrary.</li></ul></li><li>Recommendations on the choice, dose, and delivery of bronchodilator, and how long after inhalation spirometry should be done, are based on expert opinion from previous external reviewers of this CKS topic, a guideline on diagnostic spirometry in primary care published by the GP Airways Group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Levy et al, 2009</a>] and the primary care commissioning (PCC) <em>Guide to Performing Quality Assured Diagnostic Spirometry</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">PCC, 2013</a>].</li></ul></li><li><strong>Imaging </strong>— clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GINA and GOLD, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">All Wales Medicine Strategy Group, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>] recommend chest X-ray to help exclude other causes of symptoms.<ul><li>Be aware that emphysema on CT scan is an independent risk factor for lung cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>].</li></ul></li><li><strong>Full blood count</strong> is recommended to identify anaemia and polycythaemia. In addition, in some people with COPD there may be an increase in eosinophils [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">All Wales Medicine Strategy Group, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>].</li><li>Recommendation on additional investigations<strong> </strong>(such as sputum culture, peak flow and cardiac investigations) are taken from the NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>].</li></ul></li></ul><h4>Differential diagnosis</h4><p>The information on the differential diagnosis of COPD is based on the clinical guideline <em>Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 report</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Gentry, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Hangaard, 2017</a>].</p><!-- end field f840d9b5-3113-4208-9b5c-a76e00dbf279 --><!-- end item 99bb0040-282b-4a66-b432-a76e00dbf05c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}